RFRafael Christophe Freire

Rafael Christophe Freire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rafael Christophe Freire has a total of 306 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Content Validation and Usability of an Educational Booklet on Non-Suicidal Self-Injury in Adolescents

    by Katiane da Silva Mendonça, Ingrid Martins Leite Lúcio, Rafael Christophe da Rocha Freire, Ana Paula Nogueira de Magalhães, Jorgina Sales Jorge, Verônica de Medeiros Alves

    Introduction: Non-suicidal self-injury in adolescents constitutes a growing public health problem, for which there is still a lack of validated educational materials to assist healthcare and education professionals in identifying and adequately managing these cases. Objective: To analyze the evidence regarding the content validity and usability of an educational booklet on non-suicidal self-injury in adolescents. Materials and Methods: The study was conducted in four stages: Initial development of the booklet; preliminary review; evaluation by specialist judges and school professionals; and subsequent revisions. The sample included 10 judges selected through an analysis of their résumés on the Lattes Platform, based on criteria such as academic qualifications, experience in the field, teaching experience, and scientific output, as well as 22 school professionals, selected through snowball sampling, with experience in providing academic support to adolescents. The booklet, titled Marcas que doem (Scars that Hurt), which contains 42 pages and 14 topics, was developed based on a scoping review of school practices regarding non-suicidal self-injury. For content validation, the Suitability Assessment of Materials instrument was used to calculate the content validity index; for usability, the System Usability Scale was applied. Results: The overall content validity index was 0.9, which is considered excellent. The mean score on the System Usability Scale indicated excellent usability, with 84.6% of the professionals considering the booklet suitable for use in schools. Conclusion: The booklet provides evidence of content validity and usability, making it a valuable educational resource to support health and education professionals in the prevention and care of non-suicidal self-injury in adolescents.

  • Open Access

    Fear Circuits in Panic Disorder: An Update

    by Peter Kyriakoulis, Rafael Christophe da Rocha Freire

    Objectives: Findings from animal models have been instrumental in elucidating the mechanisms and etiology of panic disorder (PD); nonetheless, several aspects of its neurobiological underpinnings remain to be fully clarified. This review aims to consolidate current understanding and recent advances in the neuroanatomical and pathophysiological basis of PD. Method: A narrative review was conducted, drawing on recent literature addressing the neurobiology and neuroanatomy of PD, with a particular focus on fear circuits as elucidated by both preclinical and clinical studies. Results: This updated review further delineates the fear circuitry implicated in PD, emphasizing the roles of the amygdala, thalamus, hippocampus, insula, and prefrontal cortex in the mediation of pathological fear responses. Conclusion: Continued research involving human populations is essential to refine current models of fear circuitry in PD. Such efforts may yield critical insights that support the development of evidence-based therapeutic strategies aimed at re-establishing disrupted homeostatic processes that have been disrupted by the activation of the brain’s fear circuitry.


  • Open Access

    Neurocircuitry and Neuroanatomy in Panic Disorder: A Systematic Review

    by Peter Kyriakoulis, Clarissa Wijaya, Laiana Quagliato, Rafael C. Freire, Antonio E. Nardi

    Background: This review updates our understanding of the neuroanatomical and neurocircuitry factors involved in panic disorder (PD). Many aspects remain undetermined. Methods: Clinical studies and a randomized controlled trial were identified via PubMed database and included in this review. Results: The search, following PRISMA guidelines, identified 13 human studies and 3 animal studies. Nine human studies compared brain activity and connectivity between regions in PD patients. Neural activity in the amygdala was highlighted in six studies. The hippocampus had higher activation in PD patients compared to those with social phobia, but generally showed less activity compared to healthy controls. The parahippocampal gyrus and thalamus exhibited greater activation in PD patients than healthy controls. Activity in the prefrontal cortices was also noted, particularly the ventromedial prefrontal cortex (vmPFC), ventrolateral prefrontal cortex (vlPFC), dorsomedial prefrontal cortex (dmPFC), and dorsolateral prefrontal cortex (dlPFC). Other regions involved included the dorsal midbrain, left brainstem (showing hyperactivation), S1, and right caudate, which showed increased activity in PD patients. The left intraparietal sulcus (IPS) exhibited hypoactivation in response to predictable cues compared to unpredictable or neutral cues within the default mode network (DMN). Three animal studies suggested that electrical and chemical activation of the dorsal periaqueductal gray (dPAG) in rats elicited fight-or-flight behaviors, providing a model for panic attacks. Conclusions: Neuroimaging studies suggest several key regions involved in PD pathophysiology, including the brainstem, amygdala, hippocampus, parahippocampal gyrus, thalamus, insula, and prefrontal and cingulate cortices. Hypersensitivity in the brainstem and amygdala plays a role in activating the fear network. Further prospective studies are needed to identify the neuroanatomical sites involved in PD and fear circuitry.


  • Open Access

    Capnometry-Guided Respiratory Intervention in Veteran PTSD: Impact on Symptom Clusters

    by Robert N. Cuyler, Juliette S. Mojgani, Julio Cezar Albuquerque da Costa, Rafael C. Freire

    Background/Objectives: Post-traumatic stress disorder (PTSD) is a challenging psychiatric condition to treat, with suboptimal recovery and difficulty tolerating exposure-based psychotherapies often noted in outcomes research. The aim of this study was to examine patterns of symptom reduction in veterans with PTSD treated with a Capnometry-Guided Respiratory Intervention (CGRI), a 28-day treatment teaching about the normalization of respiratory rate and exhaled carbon dioxide levels via biofeedback. We hypothesized reductions in total PCL-5 scores and all symptom clusters immediately post-treatment but with relative resistance to changes in hyperarousal symptoms, as reported in the outcomes of research using other evidence-based psychotherapies. Methods: In this report of real-world outcomes, we included 164 veterans treated with CGRI. Pre- and post-treatment PTSD Checklists for DSM-5 (PCL-5) scales were recorded and analyzed based on the total, cluster, and item scores. Subjects were additionally classified into Recovered, Improved, or Suboptimal subgroups based on their response to treatment. Data were compiled during routine clinical care and are available for retrospective analysis. Results: Treatment response was reported in 53% of participants, with a mean total PCL-5 score reduction of 12 points post-treatment (effect size, Glass’s Δ = 0.99, large) and individual PCL-5 clusters showing medium to large effect sizes (effect size = 0.71 to 0.98). Contrary to our hypothesis, a large effect size was found in the hyperarousal cluster, with post-treatment scores being significantly improved compared to pre-treatment scores (effect size = 0.98). In the Recovered group, all 20 PCL-5 items showed significant declines, while significant reductions were reported in some items in the Improved group and no item improvements were noted in the Suboptimal group. Conclusions: Consistently with prior published trials reporting overall improvements in PTSD symptoms, in this report, the CGRI produced clinically meaningful reductions in PCL-5 cluster scores in addition to total scores. Unlike reports from several trials of cognitive therapies, this study found hyperarousal symptoms to be responsive to treatment. The CGRI shows evidence of improvement across the range of PTSD symptoms in the immediate post-treatment interval. The absence of an extended post-treatment follow up introduces uncertainty concerning the durability of benefits experienced, although previous CGRI research on both panic disorder and PTSD has shown the maintenance of symptom reduction in six- to twelve-month intervals.

  • Open Access

    Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis

    by Marcos Fidry, Morena Mourao Zugliani, Mariana Costa Do Cabo, Renan Machado Martins, Manuella Assad Gomez, Clara Gitahy Falcão Faria, Antonio Egidio Nardi, Rafael C. Freire

    Background: Many pharmacological treatments are considered effective in the treatment of panic disorder (PD), however, about 20 to 40% of the patients have treatment-resistant PD. Pharmacogenetics could explain why some patients are treatment-resistant. Objective: Our objective was to gather preliminary data on the clinical usefulness of pharmacogenetic testing in this disorder. Methods: Twenty patients with treatment-resistant PD were included in this observational study and submitted to commercial pharmacogenetic testing. Testing panel included gene polymorphisms related to CYP, genes EPHX1, UGT1A4, UGT2B15, ABCB1, ADRA2A, ANKK1, COMT, DRD2, FKBP5, GRIK4, GSK3B, HTR1A, HTR2A, HTR2C, MC4R, OPRM1, SCN1A, SLC6A4 and MTHFR. Participants received treatment-as-usual for PD before being enrolled in this study, including first-line and second-line medications for PD. Results: In 30% of the patients, the tests indicated reduced chance of response to the prescribed drug, while they indicated very low serum levels of the prescribed drug in 20% of the subjects. The pharmacogenetic tests predicted reduction of MTHFR enzyme activity in 74% of the patients. ABCB1 gene alleles associated to drug resistance were found in 90% of the samples. Conclusion: Commercial pharmacogenetic testing failed to predict negative treatment outcome in most patients with PD. The association between treatment-resistance in PD and the genes CYP2C19, MTHFR and ABCB1 deserves further study.


  • Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression

    by Vitor Breda, Rafael Freire

    Major depressive disorder (MDD) is a psychiatric disorder with several effective therapeutic approaches, being antidepressants and psychotherapies the first-line treatments. Nonetheless, due to side effects, limited efficacy, and contraindications for these treatments, alternative treatment options are required. Neurostimulation is a non-pharmacological and non-psychotherapeutic approach that has been under study for diverse neuropsychiatric conditions in the form of electrical or magnetic stimulation of the brain. Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulation method designed to generate magnetic fields and deliver magnetic pulses to stimulate the brain cortex. The magnetic pulses produce electrical currents in the brain which are not intense enough to provoke seizures, differentiating this method from other forms of neurostimulation that produce seizures. Although the exact rTMS mechanisms of action are not completely understood, rTMS seems to cause its beneficial effects through changes in neuroplasticity. Devices and protocols for rTMS are still evolving, becoming more efficient over time. There are still some challenges to be addressed, including further refinement of parameters (coil/device type, location, intensity, frequency, number of sessions, and duration of treatment); treatment cost and burden for patients; and treatment resistance. However, the efficacy, tolerability, and safety of some rTMS protocols have been demonstrated in different double-blind sham-controlled randomized controlled trials and meta-analyses for treatment-resistant depression.


  • Open Access

    Neurochemical and genetic factors in panic disorder: a systematic review

    by Adriana Carvalho Natal Moraes, Clarissa Wijaya, Rafael Freire, Laiana Azevedo Quagliato, Antonio Egidio Nardi, Peter Kyriakoulis

    This systematic review addresses the complex nature of Panic Disorder (PD), characterized by recurrent episodes of acute fear, with a focus on updating and consolidating knowledge regarding neurochemical, genetic, and epigenetic factors associated with PD. Utilizing the PRISMA methodology, 33 original peer-reviewed studies were identified, comprising 6 studies related to human neurochemicals, 10 related to human genetic or epigenetic alterations, and 17 animal studies. The review reveals patterns of altered expression in various biological systems, including neurotransmission, the Hypothalamic-Pituitary-Adrenal (HPA) axis, neuroplasticity, and genetic and epigenetic factors leading to neuroanatomical modifications. Noteworthy findings include lower receptor binding of GABAA and serotonin neurotransmitters in the amygdala. The involvement of orexin (ORX) neurons in the dorsomedial/perifornical region in triggering panic reactions is highlighted, with systemic ORX-1 receptor antagonists blocking panic responses. Elevated Interleukin 6 and leptin levels in PD patients suggest potential connections between stress-induced inflammatory changes and PD. Brain-derived neurotrophic factor (BDNF) and tyrosine receptor kinase B (TrkB) signaling are implicated in panic-like responses, particularly in the dorsal periaqueductal gray (dPAG), where BDNF’s panicolytic-like effects operate through GABAA-dependent mechanisms. GABAergic neurons’ inhibitory influence on dorsomedial and posterior hypothalamus nuclei is identified, potentially reducing the excitability of neurons involved in panic-like responses. The dorsomedial hypothalamus (DMH) is highlighted as a specific hypothalamic nucleus relevant to the genesis and maintenance of panic disorder. Altered brain lactate and glutamate concentrations, along with identified genetic polymorphisms linked to PD, further contribute to the intricate neurochemical landscape associated with the disorder. The review underscores the potential impact of neurochemical, genetic, and epigenetic factors on the development and expression of PD. The comprehensive insights provided by this systematic review contribute to advancing our understanding of the multifaceted nature of Panic Disorder and pave the way for targeted therapeutic strategies.


  • Antipsychotic agents in anxiety disorders: An umbrella review

    by Amir Garakani, Frank D. Buono, Mona Salehi, Melissa C. Funaro, Anna Klimowicz, Harshit Sharma, Clara G. F. Faria, Kaitlyn Larkin, Rafael C. Freire

    Background: Although not approved for the treatment of anxiety disorders (except trifluoperazine) there is ongoing off‐label, unapproved use of first‐generation antipsychotics (FGAs) and second‐generation antipsychotics (SGAs) for anxiety disorders. There have been systematic reviews and meta‐analyses on the use of antipsychotics in anxiety disorders, most of which focused on SGAs.Objective: The specific aims of this umbrella review are to: (1) Evaluate the evidence of efficacy of FGAs and SGAs in anxiety disorders as an adjunctive treatment to traditional antidepressant treatments and other nonantipsychotic medications; (2) Compare monotherapy with antipsychotics to first‐line treatments for anxiety disorders in terms of effectiveness, risks, and side effects. The review protocol is registered on PROSPERO (CRD42021237436).Methods: An initial search was undertaken to identify systematic reviews and meta‐analyses from inception until 2020, with an updated search completed August 2021 and January 2023. The searches were conducted in PubMed, MEDLINE (Ovid), EMBASE (Ovid), APA PsycInfo (Ovid), CINAHL Complete (EBSCOhost), and the Cochrane Library through hand searches of references of included articles. Review quality was measured using the AMSTAR‐2 (A MeaSurement Tool to Assess Systematic Reviews) scale.Results: The original and updated searches yielded 1796 and 3744 articles respectively, of which 45 were eligible. After final review, 25 systematic reviews and meta‐analyses were included in the analysis. Most of the systematic reviews and meta‐analyses were deemed low‐quality through AMSTAR‐2 with only one review being deemed high‐quality. In evaluating the monotherapies with antipsychotics compared with first‐line treatments for anxiety disorder there was insufficient evidence due to flawed study designs (such as problems with randomization) and small sample sizes within studies. There was limited evidence suggesting efficacy of antipsychotic agents in anxiety disorders other than quetiapine in generalized anxiety disorder (GAD).Conclusions: This umbrella review indicates a lack of high‐quality studies of antipsychotics in anxiety disorders outside of the use of quetiapine in GAD. Although potentially effective for anxiety disorders, FGAs and SGAs may have risks and side effects that outweigh their efficacy, although there were limited data. Further long‐term and larger‐scale studies of antipsychotics in anxiety disorders are needed.


  • Open Access

    Dexmedetomidine in the Treatment of Depression: An Up-to-date Narrative Review

    by Tamadhir Al-Mahrouqi, Mohammed Al Alawi, Rafael C. Freire

    Depressive disorders (DD) are common, and their prevalence is expected to rise over the next decade. Depressive disorders are linked to significant morbidity and mortality. The clinical conundrum of depressive disorders lies in the heterogeneity of their phenomenology and etiology. Further, the currently available antidepressants have several limitations, including a delayed onset of action, limited efficacy, and an unfavorable side effect profile. In this review, Dexmedetomidine (DEX), a highly selective and potent α2-adrenergic receptor (α2-AR) agonist, is proposed as a potentially novel antidepressant with multiple mechanisms of action targeting various depression pathophysiological processes. These mechanisms include modulation of the noradrenergic system, regulation of neuroinflammation and oxidative stress, influence on the Brain-Derived Neurotrophic Factor (BDNF) levels, and modulation of neurotransmitter systems, such as glutamate. The review begins with an introduction before moving on to a discussion of DEX's pharmacological features. The pathophysiological and phenomenological targets of DD are also explored, along with the review of the existing preclinical and clinical evidence for DEX's putative anti-depressant effects. Finally, the review ends by presenting the pertinent conclusions and future directions.